Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts The vast majority of adults with acute lymphoblastic leukemia (ALL) achieve remission with standard chemotherapy regimens, but many of these patients ultimately relapse and die from leukemia. In these patients, relapse occurs despite achievement of morphologic remission (ie, bone marrow blasts <5%), suggesting that low levels of measurable residual disease (MRD), also called “minimal residual disease,” persist in the remission bone marrow (Figure 1). Compared with morphologic assessment alone, sensitive methods of MRD quantification can better estimate the reduction in posttreatment disease burden and provide information about the leukemia biology and treatment response of individual patients. Posttreatment MRD status […]
Why not Stay in Touch…?
- GTC was featured in the Orange County Business Journal again
- New Collaboration to Offer Liquid Biopsy Testing
- Genomic Testing Cooperative (GTC) Receives Medicare (Palmetto GBA) Coverage for GTC-Solid Tumor Profile (434 gene) Test
- American Society of Hematology Meeting 2019: PRESENTATION POSTERS
- Genomic Testing Cooperative to Present at American Society of Hematology Annual Meeting 2019
acute myeloid leukemia Adult AI AML apoptosis B-Cell Lymphoma beta 2-Microglobulin Biological Biological Processes Biomarkers bone marrow BTK Case Study chemotherapy Clinically relevant CLL Congress Diseases DNA profiling enzyme inhibitors genetic profiling genomic testing Genomic Testing Cooperative gtc hematology ibrutinib Janus Kinase 2 Ki-67 Antigen leukemia liquid biopsy Lymphoid Malignancies Myeloid Malignancies ngs Non-Biological PLCγ2 press release Receptors resistance RNA sequencing Study Population Technology and Procedures Therapies Thrombopoietin TKI Young Adult